Table 1 Clinicopathological characteristics of the 152 breast cancer patients
Characteristic | Number (%) |
|---|---|
Gender | |
Female | 152 (100) |
Male | 0 (0) |
Age | |
≤55 | 80 (52.6) |
>55 | 72 (47.4) |
Mean (±SD) | 56.0 (12.4) |
Tumor size (T-status) | |
T1 (0–20 mm) | 77 (50.7) |
T2 (20–50 mm) | 68 (44.7) |
T3 (>50 mm) | 7 (4.6) |
(T2-T3) | (75 (49.3)) |
Grade | |
G1 (well differentiated) | 21 (13.8) |
G2 (moderately differentiated) | 53 (34.9) |
(G1-G2) | (74 (48.7)) |
G3 (poorly differentiated) | 78 (51.3) |
Estrogen receptor (ER) status | |
Negative | 35 (23.0) |
Positive | 117 (77.0) |
Progesterone receptor (PR) status | |
Negative | 51 (33.6) |
Positive | 101 (66.4) |
Human epidermal growth factor receptor 2 (HER2) status | |
Negative | 137 (90.1) |
Positive | 15 (9.9) |
Hormone receptor (HR) negative status (ER/PR negative) | |
Yes | 34 (22.4) |
No | 118 (77.6) |
Triple negative (TN) status (ER/PR/HER2 negative) | |
Yes | 29 (19.1) |
No | 123 (80.9) |
Lymph node (N) status | |
N0 (0 lymph nodes) | 98 (64.5) |
N1 (1–3 lymph nodes) | 40 (26.3) |
N2 (4–9 lymph nodes) | 11 (7.2) |
N3 (≥10 lymph nodes) | 3 (2.0) |
(N1-N2-N3)a | (54 (35.5)) |
Molecular tumor subtypes (PAM50 signatures) | |
Basal | 25 (16.7) |
HER2 enriched | 15 (10.0) |
Luminal A | 63 (42.0) |
Luminal B | 39 (26.0) |
Normal-like | 8 (5.3) |